| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Kala Pharmaceuticals, Inc. | Director | Common Stock | 2,877,006 | $19,391,020 | $6.74 | 17 Jun 2021 | By Longitude Venture Partners II, L.P. |
| Kala Pharmaceuticals, Inc. | Director | Common Stock | 2,534,854 | $17,084,916 | $6.74 | 17 Jun 2021 | By Longitude Venture Partners IV, L.P. |
| Kala Pharmaceuticals, Inc. | Director | Common Stock | 40,000 | $269,600 | $6.74 | 17 Jun 2021 | Direct |
| 89bio, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 27,400 | 09 Feb 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ETNB | 89bio, Inc. | 09 Feb 2023 | 1 | $0 | 4 | Director, 10%+ Owner | 13 Feb 2023, 16:34 |
| ETNB | 89bio, Inc. | 16 May 2022 | 1 | $0 | 4 | Director | 18 May 2022, 16:05 |
| KALA | Kala Pharmaceuticals, Inc. | 17 Jun 2021 | 1 | $0 | 4 | Director | 21 Jun 2021, 17:30 |